Cornerstone Therapeutics Inc. Reports First Quarter 2013 Financial Results
5/9/2013 11:04:23 AM
More...
|
Cornerstone Therapeutics Inc. Acquires Exclusive U.S. Marketing Rights to PERTZYE® (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
5/9/2013 11:02:17 AM
More...
|
Cornerstone Therapeutics Inc. to Host First Quarter 2013 Conference Call
5/3/2013 10:54:09 AM
More...
|
Cornerstone Therapeutics Inc. Announces Retention of Advisors
3/21/2013 9:47:19 AM
More...
|
Cornerstone Therapeutics Inc. Reports Fourth Quarter and Fiscal Year 2012 Financial Results
3/14/2013 9:18:16 AM
More...
|
Cornerstone Therapeutics Inc. to Host Fourth Quarter and Full Year 2012 Conference Call
3/8/2013 8:41:32 AM
More...
|
Cornerstone Therapeutics Inc. Announces Appointment of Special Committee
2/26/2013 9:25:57 AM
More...
|
Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder
2/20/2013 9:16:03 AM
More...
|
Cornerstone Therapeutics Inc. Acquires Exclusive U.S. Rights to Chiesi Farmaceutici SpA's BETHKIS® (Tobramycin Inhalation Solution)
11/8/2012 9:21:39 AM
More...
|
Cornerstone Therapeutics Inc. Reports Third Quarter 2012 Financial Results
11/8/2012 9:20:23 AM
More...
|
|